California State Teachers Retirement System Purchases 1,070 Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT)

California State Teachers Retirement System increased its position in shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) by 3.0% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 36,450 shares of the company’s stock after purchasing an additional 1,070 shares during the period. California State Teachers Retirement System owned about 0.11% of RAPT Therapeutics worth $669,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of RAPT. Federated Hermes Inc. bought a new position in shares of RAPT Therapeutics during the 1st quarter worth about $321,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in RAPT Therapeutics by 683.2% during the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,083 shares of the company’s stock worth $93,000 after acquiring an additional 4,434 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in RAPT Therapeutics by 40.9% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 16,688 shares of the company’s stock worth $306,000 after acquiring an additional 4,843 shares in the last quarter. Jump Financial LLC bought a new position in shares of RAPT Therapeutics during the first quarter valued at $619,000. Finally, SG Americas Securities LLC acquired a new stake in shares of RAPT Therapeutics in the 1st quarter valued at $240,000. 99.09% of the stock is owned by institutional investors.

RAPT Therapeutics Price Performance

Shares of RAPT Therapeutics stock opened at $20.15 on Tuesday. The firm has a 50 day simple moving average of $21.02 and a 200 day simple moving average of $21.06. RAPT Therapeutics, Inc. has a fifty-two week low of $15.59 and a fifty-two week high of $31.45. The firm has a market cap of $692.35 million, a P/E ratio of -7.49 and a beta of 0.40.

RAPT Therapeutics (NASDAQ:RAPT) last released its earnings results on Friday, August 11th. The company reported ($0.66) EPS for the quarter, beating the consensus estimate of ($0.78) by $0.12. On average, sell-side analysts expect that RAPT Therapeutics, Inc. will post -2.95 EPS for the current year.

Analysts Set New Price Targets

RAPT has been the subject of a number of recent analyst reports. Piper Sandler increased their target price on shares of RAPT Therapeutics from $28.00 to $31.00 and gave the stock an “overweight” rating in a research report on Monday, August 14th. HC Wainwright reaffirmed a “buy” rating and set a $41.00 price objective on shares of RAPT Therapeutics in a report on Monday, August 14th. JPMorgan Chase & Co. reduced their target price on RAPT Therapeutics from $39.00 to $32.00 and set an “overweight” rating on the stock in a report on Wednesday, August 16th. Stifel Nicolaus assumed coverage on RAPT Therapeutics in a report on Tuesday, August 8th. They set a “buy” rating and a $40.00 price target for the company. Finally, Barclays assumed coverage on RAPT Therapeutics in a research note on Thursday, June 15th. They issued an “overweight” rating and a $35.00 price objective on the stock. Nine research analysts have rated the stock with a buy rating, According to MarketBeat, RAPT Therapeutics has a consensus rating of “Buy” and an average price target of $38.60.

Insider Buying and Selling

In other RAPT Therapeutics news, insider William Ho sold 2,500 shares of the company’s stock in a transaction dated Friday, August 18th. The shares were sold at an average price of $18.92, for a total transaction of $47,300.00. Following the transaction, the insider now directly owns 21,289 shares in the company, valued at approximately $402,787.88. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Corporate insiders own 5.50% of the company’s stock.

RAPT Therapeutics Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.